A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection.
Phase of Trial: Phase III
Latest Information Update: 11 Jun 2019
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 25 Oct 2016 Status changed from active, no longer recruiting to completed.
- 06 Oct 2016 This trial has been completed in Spain as per European Clinical Trials Database record.
- 01 Oct 2016 This trial has been completed in Germany as per European Clinical Trials Database record.